Investigational drug · Phase 3
JMKX003142
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Renal Edema, Nephrogenic Edema, Edema Secondary.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
12
Any phase or sponsor naming "JMKX003142"
First trial start
2025
Jul 9, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JMKX003142", any sponsor or status.
Conditions studied
As listed on its trial records.
- Renal Edema
- Nephrogenic Edema
- Edema Secondary
- Edema Leg
- Cardiac Edema
Approved drugs for the same conditions: Cardiovascular and metabolic · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "JMKX003142" as an intervention, largest first.
- A Study of JMKX003142 Tablet to Treat Renal EdemaPivotal-lookingNot yet recruiting
JemincareIndustry
NCT07841093 · 240 participants (planned) · Start Feb 28, 2027 · Primary completion Apr 30, 2028
Drug: JMKX003142 Tablets; Placebo Tablets · For: Renal Edema; Nephrogenic Edema
Sites: Shanghai, China
- A Dose-finding Study of JMKX003142 in Treatment of Cardiac EdemaPivotal-lookingCompleted
JemincareIndustry
NCT06949020 · 160 participants · Start Jul 9, 2025 · Primary completion Mar 14, 2026
Drug: JMKX003142 Injection; JMKX003142 Injection and 2 more · For: Cardiac Edema
Sites: Hangzhou, China
- Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)Pivotal-lookingRecruiting
JemincareIndustry
NCT06800651 · 135 participants (planned) · Start Mar 13, 2025 · Primary completion Feb 28, 2027
Drug: JMKX003142 will be administered orally; Plcacebo · For: ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Sites: Beijing, China
- A Dose-finding Study of JMKX003142 in Treatment of Renal EdemaPivotal-lookingCompleted
JemincareIndustry
NCT06670534 · 133 participants · Start Oct 17, 2025 · Primary completion Apr 27, 2026
Drug: JMKX003142 tablets; Placebo Tablets · For: Edema Secondary; Edema Leg
Sites: Shanghai, China · 2 sites in all
- Drug-Drug Interactions of JMKX003142 in Healthy ParticipantsNot yet recruiting
JemincareIndustry
NCT07565441 · 112 participants (planned) · Start May 11, 2026 · Primary completion Nov 15, 2026
Drug: JMKX003142 tablets; Fluconazole Capsules and 7 more · For: ADPKD (Autosomal Dominant Polycystic Kidney Disease)
- Phase 1 Clinical Study of JMKX003142 TabletsPivotal-lookingStatus unknown
JemincareIndustry
NCT06079541 · 106 participants (planned) · Start Jul 6, 2023 · Primary completion Jul 31, 2024
Drug: JMKX003142 will be administered orally; JMKX003142 will be administered orally and 3 more · For: Safety and Tolerability
Sites: Shanghai, China
JemincareIndustry
NCT06344533 · 78 participants (planned) · Start Apr 10, 2024 · Primary completion Jan 31, 2025
Drug: JMKX003142 Injection; Placebo · For: Healthy Adult
Sites: Beijing, China
JemincareIndustry
NCT06658964 · 48 participants (planned) · Start Nov 5, 2024 · Primary completion Dec 10, 2024
Drug: Cohort 1: JMKX003142 and itraconazole; Cohort 2: JMKX003142 and rifampicin · For: ADPKD (autosomal Dominant Polycystic Kidney Disease)
- Drug-Drug Interaction of JMKX003142 With Amiodarone and Febuxostat in Healthy SubjectsNot yet recruiting
JemincareIndustry
NCT07181265 · 48 participants (planned) · Start Oct 30, 2025 · Primary completion Apr 30, 2026
Drug: Amiodarone Hydrochloride Tablets; Febuxostat Tablets · For: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- A Study to Investigate the Pharmacokinetics of JMKX003142 in Healthy Participants and Participants With Hepatic ImpairmentNot yet recruiting
JemincareIndustry
NCT07909070 · 32 participants (planned) · Start Nov 20, 2026 · Primary completion May 30, 2027
Drug: JMKX003142 · For: ADPKD (Autosomal Dominant Polycystic Kidney Disease); Renal Edema
Newest research
PubMed records naming it or its code names, newest first.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.